Phospho-DAPK2 (S318) Antibody

What is Phospho-DAPK2 (S318) Antibody and what does it specifically detect?

Phospho-DAPK2 (S318) Antibody is a polyclonal antibody that specifically detects endogenous levels of Death-associated protein kinase 2 (DAPK2) only when phosphorylated at serine 318. This antibody is typically raised in rabbits and is generated using synthesized peptides derived from human DAPK2 around the phosphorylation site of Ser318, generally spanning amino acids 284-333 . The antibody allows researchers to specifically study the phosphorylation status of DAPK2 at this critical regulatory site, which has significant implications for the protein's kinase activity and cellular functions .

What applications is this antibody validated for?

Phospho-DAPK2 (S318) Antibody has been validated for multiple research applications with specific dilution recommendations:

These dilution ranges provide starting points for optimization. Researchers should perform titration experiments to determine the optimal concentration for their specific experimental conditions .

What species reactivity has been confirmed for this antibody?

The Phospho-DAPK2 (S318) Antibody has confirmed reactivity against multiple species:

• Human

• Mouse

• Rat

This cross-reactivity stems from the high conservation of the sequence around the S318 phosphorylation site across these species . This makes the antibody versatile for comparative studies across different model systems.

What are the optimal storage conditions for maintaining antibody activity?

For maximum preservation of antibody activity, Phospho-DAPK2 (S318) Antibody should be stored according to these guidelines:

• Long-term storage: -20°C for up to one year

• Short-term/frequent use: 4°C for up to one month

• Formulation: Typically provided as liquid in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide

• Important precaution: Avoid repeated freeze-thaw cycles

To maintain antibody integrity when working with the reagent, keep it on ice during experiments and return to storage promptly after use. For frequent access, preparing small aliquots before freezing is recommended to minimize freeze-thaw damage .

What is the biological significance of DAPK2 phosphorylation at S318?

Phosphorylation at serine 318 serves as a critical regulatory mechanism for DAPK2 function with several key implications:

• Autoinhibitory mechanism: Autophosphorylation at S318 inhibits DAPK2's catalytic activity, functioning as a negative regulatory mechanism

• Signal response: S318 becomes dephosphorylated in response to activated Fas and TNF-alpha receptors, releasing the inhibition and activating DAPK2's pro-apoptotic functions

• Functional switch: The phosphorylation status determines whether DAPK2 promotes cell survival or death signaling pathways

• Mitochondrial integrity: The kinase domain regulated by S318 phosphorylation is crucial for maintaining mitochondrial function, as evidenced by enhanced oxidative stress when kinase-dead DAPK2 mutants are overexpressed

This phosphorylation site represents a critical molecular switch that determines DAPK2's activity status and downstream cellular effects .

How does DAPK2 contribute to cellular metabolism and mitochondrial function?

Research has revealed that DAPK2 plays significant roles in maintaining mitochondrial integrity and metabolic homeostasis:

These findings establish DAPK2 as a regulator of mitochondrial function and cellular metabolism beyond its well-established roles in cell death pathways, positioning it at a crucial intersection of survival and death mechanisms .

What is known about DAPK2's role in different cell death mechanisms?

DAPK2 exhibits versatile regulatory functions in both apoptotic and autophagic cell death:

• Dual regulation: DAPK2 can regulate both type I apoptotic (caspase-dependent) and type II autophagic (caspase-independent) cell death pathways depending on cellular context

• Autophagic processes: DAPK2 has been localized to cytoplasmic vesicles and autophagosome lumens, suggesting direct involvement in autophagic machinery

• Apoptotic signaling: DAPK2 functions as a calcium/calmodulin-dependent serine/threonine kinase that positively regulates apoptosis when activated

• Cell adhesion: DAPK2 serves as a mediator of anoikis (detachment-induced cell death) and suppresses β-catenin-dependent anchorage-independent growth of malignant epithelial cells

• Granulocytic regulation: DAPK2 may play roles in granulocytic maturation and motility by controlling cell spreading and polarization

The phosphorylation status at S318 serves as a critical determinant of which death pathway DAPK2 will promote in specific cellular contexts .

What controls should be included when using Phospho-DAPK2 (S318) Antibody?

For rigorous experimental design with Phospho-DAPK2 (S318) Antibody, include these essential controls:

• Positive control: Unstimulated cells with basal phosphorylation of DAPK2 at S318

• Negative controls:

  • DAPK2 knockout/knockdown samples

  • Phosphatase-treated samples to remove phosphorylation

  • Fas or TNF-alpha treated samples (as these stimuli induce S318 dephosphorylation)

• Specificity validation:

  • Peptide competition assay using the immunizing phosphopeptide

  • Parallel analysis with a total DAPK2 antibody to normalize phospho-signal to total protein

• Technical controls:

  • Secondary antibody-only control to identify non-specific binding

  • Isotype control (non-specific rabbit IgG) at matching concentration

  • Treatment validation using kinase inhibitors that affect DAPK2 phosphorylation

This comprehensive set of controls ensures that observed signals truly represent phosphorylated DAPK2 at S318 rather than experimental artifacts .

What methodological approaches can distinguish between apoptotic and autophagic roles of DAPK2?

To differentiate between DAPK2's involvement in apoptotic versus autophagic cell death, consider these methodological approaches:

• Co-localization analysis: Perform immunofluorescence using Phospho-DAPK2 (S318) Antibody (1:200-1:1000 dilution) alongside markers for:

  • Apoptosis (cleaved caspase-3, PARP cleavage)

  • Autophagy (LC3-II puncta, Beclin-1)

• Pathway inhibition studies: Analyze DAPK2 phosphorylation status after treatment with:

  • Apoptosis inhibitors (Z-VAD-FMK, caspase inhibitors)

  • Autophagy inhibitors (3-methyladenine, chloroquine)

• Time-course experiments: Monitor S318 phosphorylation status across time following various death-inducing stimuli, correlating DAPK2 activation with the emergence of apoptotic or autophagic morphological features

• Mitochondrial function assessment: Since DAPK2 regulates mitochondrial integrity, measure parameters such as:

  • Mitochondrial membrane potential using potentiometric dyes

  • ROS production using specific probes

  • Oxygen consumption rate

• Genetic manipulation: Compare effects of wild-type DAPK2 versus phosphomimetic (S318D/E) or phosphodeficient (S318A) mutants on cell death phenotypes

These approaches collectively help position DAPK2 activation within specific cell death signaling cascades in different cellular contexts .

How can researchers troubleshoot non-specific binding with this antibody?

When encountering non-specific binding with Phospho-DAPK2 (S318) Antibody, implement these troubleshooting strategies:

• Optimize antibody dilution: Test multiple dilutions within the recommended ranges (IHC: 1:100-1:300; IF: 1:200-1:1000; ELISA: 1:5000) to identify the optimal signal-to-noise ratio

• Improve blocking: Extend blocking times or test different blocking reagents (BSA, normal serum, commercial blockers) to reduce non-specific binding sites

• Enhance washing protocol:

  • Increase wash buffer volume

  • Extend washing duration

  • Add detergents (0.1-0.3% Tween-20) to remove weakly bound antibodies

• Adjust sample preparation:

  • Optimize fixation conditions (formaldehyde concentration, fixation time)

  • Test different antigen retrieval methods (heat-induced vs. enzymatic)

  • Consider sample-specific modifications for phosphoepitope preservation

• Secondary detection modifications:

  • Reduce secondary antibody concentration

  • Try alternative detection systems (fluorescent vs. enzymatic)

  • Use highly cross-adsorbed secondary antibodies

• Implement validation studies:

  • Peptide competition assays

  • Parallel testing on DAPK2-depleted samples

  • Use complementary techniques (Western blot, mass spectrometry)

Systematic optimization of these parameters should help distinguish specific phospho-DAPK2 signal from background artifacts .

What integrated experimental approaches can provide comprehensive insights into DAPK2 signaling?

For multidimensional analysis of DAPK2 signaling, integrate these complementary techniques with Phospho-DAPK2 (S318) Antibody:

• Phosphoproteomics integration:

  • Use mass spectrometry to identify other phosphorylation events occurring simultaneously with S318 dephosphorylation

  • Map the broader phosphorylation network affected by DAPK2 activation states

• Multi-parametric flow cytometry:

  • Simultaneously assess DAPK2 phosphorylation status, apoptotic markers, autophagic flux, and cell cycle distribution at single-cell resolution

  • This reveals heterogeneity in cellular responses to DAPK2 activation

• Live-cell imaging with biosensors:

  • Develop FRET-based biosensors for real-time monitoring of DAPK2 kinase activity

  • Correlate with subcellular localization using fluorescently-tagged DAPK2 constructs

• CRISPR-Cas9 genome editing:

  • Generate S318 phosphomimetic (S318D/E) or phosphodeficient (S318A) mutants

  • Analyze downstream phenotypic effects on mitochondrial function, cell survival, and death pathways

• Transcriptomic analysis:

  • Compare gene expression profiles between cells with different DAPK2 phosphorylation states

  • Identify transcriptional networks influenced by DAPK2 activity

• Metabolic profiling:

  • Measure metabolic flux parameters (oxygen consumption, extracellular acidification)

  • Connect DAPK2 phosphorylation status to metabolic reprogramming

This multifaceted approach provides mechanistic insights into how S318 phosphorylation influences DAPK2's diverse cellular functions .

How can researchers quantitatively analyze changes in DAPK2 phosphorylation at S318?

For robust quantification of DAPK2 phosphorylation at S318, consider these methodological approaches:

• Western blot quantification:

  • Use dual detection with phospho-specific and total DAPK2 antibodies

  • Calculate phospho/total ratio after densitometric analysis

  • Include multiple biological replicates for statistical validity

• Quantitative immunofluorescence:

  • Employ consistent imaging parameters across experimental conditions

  • Use software like ImageJ or CellProfiler for intensity measurements

  • Normalize phospho-signal to total DAPK2 or other cellular markers

• ELISA-based quantification:

  • Develop sandwich ELISA with capture antibodies against total DAPK2

  • Detect with Phospho-DAPK2 (S318) Antibody at 1:5000 dilution

  • Generate standard curves using recombinant phosphorylated and non-phosphorylated proteins

• Mass spectrometry:

  • Use selected reaction monitoring (SRM) or parallel reaction monitoring (PRM)

  • Target the phosphorylated and non-phosphorylated forms of the S318-containing peptide

  • Calculate stoichiometry of phosphorylation at this site

• High-content imaging:

  • Perform automated microscopy of cell populations

  • Analyze subcellular distribution and intensity of phospho-DAPK2 staining

  • Correlate with morphological features or other cellular markers

When reporting quantitative changes, include statistical analysis, clearly state normalization methods, and acknowledge the dynamic range and sensitivity limits of the chosen technique .

What are the limitations of using this antibody in specific experimental contexts?

Researchers should be aware of these potential limitations when working with Phospho-DAPK2 (S318) Antibody:

• Epitope accessibility challenges:

  • The S318 phosphorylation site may be masked in certain fixed samples or protein conformations

  • Different fixation methods may affect epitope recognition

  • Subcellular localization may influence accessibility

• Temporal dynamics considerations:

  • Phosphorylation is highly dynamic and can change during sample processing

  • Rapid fixation may be necessary to capture the true in vivo state

  • Phosphatase inhibitors should be included in all buffers

• Technical constraints:

  • Lot-to-lot variation in polyclonal antibody preparations

  • Cross-reactivity with similar phosphorylation motifs in other proteins

  • Limited sensitivity for detecting low-abundance phosphorylated DAPK2

• Context-dependent interpretation:

  • Phosphorylation patterns vary across cell types, tissues, and conditions

  • Baseline phosphorylation levels differ in various physiological states

  • Other post-translational modifications near S318 might affect antibody binding

• Methodological restrictions:

  • Semi-quantitative methods like IHC or IF provide relative rather than absolute quantification

  • The dilution ranges (IHC: 1:100-1:300; IF: 1:200-1:1000) may require optimization for each application

Understanding these limitations helps researchers design appropriate experiments with necessary controls and complementary approaches to validate findings related to DAPK2 phosphorylation .

What emerging questions remain about DAPK2 phosphorylation dynamics?

Several critical questions about DAPK2 S318 phosphorylation dynamics remain to be fully explored:

• Spatial regulation:

  • How does phosphorylation status affect DAPK2's subcellular distribution between cytoplasm, mitochondria, and autophagosomes?

  • Are there tissue-specific patterns of S318 phosphorylation across different organ systems?

• Temporal dynamics:

  • What are the precise kinetics of S318 dephosphorylation and re-phosphorylation during cellular responses?

  • How is DAPK2 phosphorylation regulated throughout the cell cycle and differentiation processes?

• Regulatory mechanisms:

  • Which phosphatases are responsible for S318 dephosphorylation in response to different stimuli?

  • How do other post-translational modifications interact with S318 phosphorylation?

• Pathological implications:

  • How is DAPK2 S318 phosphorylation altered in disease states such as cancer or neurodegeneration?

  • Could targeting this phosphorylation site have therapeutic potential?

• Evolutionary conservation:

  • How conserved is the regulatory mechanism of S318 phosphorylation across species?

  • Do different isoforms of DAPK2 show distinct phosphorylation patterns or regulation?

Addressing these questions will require integrated approaches combining Phospho-DAPK2 (S318) Antibody with advanced technologies such as live-cell imaging, phospho-specific biosensors, and systems biology approaches .